Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 pembrolizumab trial in advanced solid tumors
NL-OMON59414Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Feb 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in anal squamous cell carcinoma (SCCA), biliary adenocarcinoma, apudoma (NET) and 9 more (4 arms), sponsored by Merck & Co. Primary endpoint: Objective Response Rate. Started Feb 2016; status: active, not recruiting.
02
Drugs
03
Conditions
anal squamous cell carcinoma (SCCA)biliary adenocarcinomaapudoma (NET)endometrial cancer (EC)cervical squamous cell carcinoma (CSCC)
Beyond the preview
Go deeper on NL-OMON59414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59414.